6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial-Reference-Cited by-同舟云学术

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

Published:2013-07 Issue:8 Volume:14 Page:741-748
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Pivot Xavier,Romieu Gilles,Debled Marc,Pierga Jean-Yves,Kerbrat Pierre,Bachelot Thomas,Lortholary Alain,Espié Marc,Fumoleau Pierre,Serin Daniel,Jacquin Jean-Philippe,Jouannaud Christelle,Rios Maria,Abadie-Lacourtoisie Sophie,Tubiana-Mathieu Nicole,Cany Laurent,Catala Stéphanie,Khayat David,Pauporté Iris,Kramar Andrew

Publisher

Elsevier BV

Subject

Oncology

Reference12 articles.

1. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Engl J Med,2005

2. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

3. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;N Engl J Med,2011

4. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer;Joensuu;N Engl J Med,2006

5. Committee for medicinal products for human use (CHMP) guideline on the choice of the non-inferiority margin;Stat Med,2006

Cited by 305 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accrual and statistical power failure in published adjuvant phase III oncology trials: a comprehensive analysis from 2013 to 2023;ESMO Open;2024-07

2. Consenso mexicano de cáncer mamario. Manejo del cáncer de mama temprano;Gaceta Mexicana de Oncolog�a;2024-06-25

3. Racial and Ethnic Disparities in European Breast Cancer Clinical Trials;Cancers;2024-04-29

4. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial;The Lancet;2024-04

5. Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam;PLOS ONE;2024-03-15